Urinary Tract Infection Treatment Market

Urinary Tract Infection Treatment Market Outlook (2021-2031)

The global urinary tract infection treatment market was valued at US$ 10.5 Bn in 2021, and is expected to increase at a CAGR of 2.1% to reach US$ 12.9 Bn by 2031.

Data Points	Market Insights
Urinary Tract Infection Treatment Market Size (2020)	US$ 10.3 Bn
Forecasted Market Value (2031)	US$ 12.9 Bn
Global Market Growth Rate (2021-2031)	2.1%
Share of Top 5 Countries	50.8%

Urinary Tract Infection Treatment Demand Analysis (2016-2020) Compared to Market Forecasts (2021-2031)

As per industry analysis by Fact.MR, a market research and competitive intelligence provider, sales of urinary tract infection treatment solutions and devices increased at a CAGR of 1.5% from 2016 to 2020.

Most pharmaceutical companies are developing antibiotics with more than one API to combat multi-drug resistant bacteria and broaden the activity spectrum of drugs. Many companies are also focusing on new drug development for uncontrolled UTI infection. Combination of products is accepted widely among physicians across the globe, and is expected to boost UTI treatment market growth over the forecast period.

Furthermore, FDA approval for new dosage forms of existing drugs is another factor that is expected to fuel development of the urinary tract infection therapeutics market over the forecast period. Also, herbal medicines for UTI treatment are gaining popularity across regions.

• In November 2020, Allergan announced FDA acceptance of Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).

Fact.MR projects the global urinary tract infection treatment market to expand at a moderate CAGR of 2.1% through 2031.

What Does the Future of UTI Infection Medicine Manufacturers Look Like?

Rising prevalence of urinary tract infections such as bladder infection, kidney infection or urethra infection, etc., and rising cases of uncomplicated urinary tract infection, are expected to boost demand for Urinary Tract Infection (UTI) treatment. Unhealthy lifestyles and high consumption of alcohol trigger chronic kidney diseases such as renal failure and bladder cancer, and this is driving kidney infection treatment demand.

Also, physicians’ preference for antibiotics for any kind of urinary tract infection is driving the antibiotics market. Collaboration of major players with research institutes are complimenting market growth by giving more treatment options for UTI treatment.

Beside antibiotics as the first line treatment for urinary tract infection, patients are looking for surgery and stimulation therapy for fast recovery. This creates demand for alternative therapies for UTI, which include a set of healthcare and medical systems and practices and products that are usually not considered to be the part of mainstream medicines, such as taking natural and herbal medicines for UTI.

Rising hospitalization rates for UTI, increasing geriatric population, and growing drug resistance are driving the interstitial cystitis market, which basically includes treatment for the chronic conditions called interstitial cystitis, and causes pain due to bladder pressure, and sometimes pelvic pain.

Driven by this, the global UTI infection medicine market is expected to rise at 2.1% CAGR through 2031.

Which Factors are Restraining Demand for Urinary Tract Infection Treatment?

Adverse effects of antibiotics are expected to hamper the urinary tract infection therapeutics market growth in the years ahead. UTI is treated with a vast range of antibiotics. However, these antibiotics have one or more adverse effects such as tendon problems, muscle weakness, allergic reactions, central nervous system-related problems, etc.

These problems can be more serious in the geriatric population, pregnant women, and children where the prevalence of UTI is higher. Additionally, continuous mutation of bacteria for existing drugs also declines market growth for UTI infection medicines to some extent for urinary tract infection treatment.

Country-wise Insights

Why is the U.S. a Leading Market for Urinary Tract Infection Treatment?

“Developed Medical Infra Driving UTI Infection Medication Sales”

The U.S. accounted for 91.4% of the North America urinary tract infection treatment market in 2021, owing to the development of many treatment facilities and rising investments in the healthcare sector. Moreover, increased rate of approvals by the U.S FDA has led to higher product penetration, making the U.S a high revenue generating country for medicines for UTI pain.

• For instance, in January 2020, Merck announced U.S. FDA approval of its drug DIFICID (fidaxomicin), which is used for the treatment of Clostridioides difficile bacteria in the pediatric population and older children.

Also, a good reimbursement scenario and rise in awareness regarding UTIs will offer lucrative opportunities for UTI treatment providers in the country.

Which Country is Leading Market UTI Market Growth in Europe?

“Germany Leading Bladder Infection Medication Demand Growth”

Germany accounted for 22.6% market share in the Europe medicines for UTI pain and treatment in 2021. Factors such as increase in geriatric population, presence of research & development programs, and high-class healthcare infrastructure are boosting demand in the urinary cystitis management market in Germany.

What’s Compelling UTI Market Players to Focus on China?

“UTI Pain Relief Medication Highly Sought-after in the Country”

China accounted for 68.9% of the East Asia market for bladder infection medications in 2021, owing to factors such as major manufacturing expansion in the country and high production capacity for antibiotic drugs.

High outsourcing potential and cost-effective production capacity for antibiotics are generating high revenue share for urinary tract infection treatment providers in China.

Category-wise Insights

Which Drug Class is Lending Traction to Market Expansion?

“Demand High for Quinolones as a Bladder Infection Medication”

By drug class, quinolones held a high share of 45.7% in 2021.  Quinolones are broadly active against most Gram-negative and Gram-positive organisms, so that multi-drug resistance is avoided in the treatment of urinary tract infection.

These drugs have the capability to improve quality of life and combat symptoms with high therapeutic effect. These lifesaving advantages of quinolones make them the most lucrative and highly adopted products across regions.

Why Complicated UTI Will Give Market Players Great Growth Potential?

“cUTI Treatment to Substantially Contribute to Market Expansion”

Demand for complicated UTI treatment is expected to rise at 2.7% CAGR over the forecast period. Urinary tract infection is one of the most common infectious disease caused by bacteria. Complicated urinary tract infection can affect anyone, irrespective of gender or age group, and is mostly related to either structural or functional abnormalities in the urinary tract.

Development of multidrug-resistance bacteria is more common in cUTI, and there has been an increase in the number of multidrug-resistance bacteria, due to which, cUTI cases are increasing across the globe.

Impact of COVID-19 Crisis

COVID-19 has had a moderately positive impact on this market due to increase in urinary tract infections in patient post COVID-19 recovery. Moreover, urinary tract infection leads to severe abdominal pain, and hence, treatment becomes mandatory.

Competitive Landscape

Companies such as Pfizer and GSK, operating in the urinary tract infection treatment market, are actively entering into partnerships and collaborations, and sometimes even divestiture of some of their business divisions to maintain a relative position in the market.

• Pfizer Inc. announced the completion of a transaction to spin off its Upjohn business and combine it with Mylan N.V. to form Viatris Inc in November 2020.
• In January 2019, GSK announced that it completed the acquisition of Tesaro for approximately US$ 5.1 Bn.

Urinary Tract Infection Treatment Report Scope

Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	USD Billion for Value
Key Countries Covered	U.S. Canada Germany U.K. France Italy Spain BENELUX Russia China Japan South Korea India Thailand Malaysia Indonesia Australia New Zealand GCC Countries Turkey South Africa
Key Market Segments Covered	Drug class Indication Distribution Channel Region
Key Companies Profiled	Bayer AG GlaxoSmithKline Pharmaceuticals Ltd. Pfizer Allergan Plc Almirall SA Bristol-Myers Squibb Merck & Co., Inc.
Report Coverage	Market Forecast Competition Intelligence DROT Analysis Market Dynamics and Challenges Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Urinary Tract Infection Treatment Industry Survey by Category

• By Drug Class:

  • Penicillin and Combinations
    • Amoxicillin
    • Amoxicillin and Clavulanate
    • Potassium
    • Others
  • Quinolones
    • Ciprofloxaxin
    • Levofloxaxin
    • Nalidixic acid
    • Norfloxacin
    • Others
  • Cephalosporin
    • Ceftriaxone
    • Cefuroxime
    • Cefixime
    • Cephalexin
  • Aminoglycoside Antibiotics
    • Amikacin
    • Gentamicin
  • Sulphonamides (Sulfamethoxazole +Trimethoprim)
  • Azoles and Amphotericin B
  • Tetracycline (Doxycycline)
  • Nirtofurans (Nitrofurantoin)
  • Other

• By Indication:

  • Complicated UTI
  • Uncomplicated UTI

• By Distribution Channel:

  • Hospital Pharmacies
  • Gynecology and Urology Clinics
  • Drug Stores
  • Retail Pharmacies
  • Online Drug Stores

• By Region:

  • North America Urinary Tract Infection Treatment Market
  • Latin America Urinary Tract Infection Treatment Market
  • Europe Urinary Tract Infection Treatment Market
  • East Asia Urinary Tract Infection Treatment Market
  • South Asia Urinary Tract Infection Treatment Market
  • Oceania Urinary Tract Infection Treatment Market
  • Middle East and Africa (MEA) Urinary Tract Infection Treatment Market